Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | XVIVO Perfusion AB: Interim Report January-March 2025 | 108 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
15.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 246 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
02.04. | XVIVO Perfusion AB: Annual Report 2024 | 233 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
20.03. | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 265 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen | |
28.01. | XVIVO Perfusion AB: Year-End Report 2024 | 216 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), corresponding... ► Artikel lesen | |
13.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2024 | 336 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen | |
26.11.24 | XVIVO Perfusion AB: Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology | 372 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in the US clinical trial "PRESERVE:... ► Artikel lesen | |
14.11.24 | XVIVO Perfusion AB: XVIVO Perfusion Appoints Lena Hagman as Deputy CEO | 250 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / November 14, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has today appointed Lena Hagman... ► Artikel lesen | |
24.10.24 | XVIVO Perfusion AB: Interim Report January-September 2024 | 299 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2024 (July 1 - September 30)• Net sales amounted to SEK 198.5 million (146.6), corresponding... ► Artikel lesen | |
10.10.24 | XVIVO Perfusion AB: Conference Call on Interim Report | 246 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / October 10, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report January-September... ► Artikel lesen | |
19.09.24 | XVIVO Perfusion AB: XVIVO to Acquire a Unique Communication Platform for the Transplant Process | 833 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / September 19, 2024 / Today, XVIVO Perfusion AB (publ) (STO:XVIVO)(LSE:0RKL)(FRA:3XV) ("XVIVO" or "the Company") has entered into an agreement to acquire the transplant... ► Artikel lesen | |
06.09.24 | Nomination Committee of XVIVO Perfusion AB | 413 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / September 6, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following members have been appointed to XVIVO Perfusion's nomination committee for the 2025... ► Artikel lesen | |
16.08.24 | XVIVO Perfusion AB: Results From European Randomized Controlled Study Using XVIVO's Heart Technology Published in The Lancet | 566 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / August 16, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, the results of the European randomized controlled clinical trial investigating the use of... ► Artikel lesen | |
12.07.24 | XVIVO Perfusion AB: Interim Report January - June 2024 | 399 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / July 12, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2024 (Apr 1 - Jun 30) • Net sales amounted to SEK 210.3 million (154.6), corresponding... ► Artikel lesen | |
25.06.24 | XVIVO Perfusion AB: Conference call on Interim Report | 253 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / June 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report April-June... ► Artikel lesen | |
25.04.24 | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 340 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / April 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion AB... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ECKERT & ZIEGLER | 57,25 | +2,05 % | EQS-News: Eckert & Ziegler SE: Eckert & Ziegler unterzeichnet Herstellungsvereinbarung mit Pentixapharm für Yttrium-90-basiertes PentixaTher | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Vereinbarung/Auftragseingänge
Eckert & Ziegler unterzeichnet Herstellungsvereinbarung mit Pentixapharm für Yttrium-90-basiertes... ► Artikel lesen | |
INTUITIVE SURGICAL | 447,95 | +0,31 % | Opening Bell: Tesla, Enphase Energy, Intuitive Surgical, Boeing, Apple, Meta, Bitcoin, Strategy | Der Optimismus verfestigt sich langsam an den US-Börsen. Gestern legten die großen Indizes bereits deutlich zu. Heute deuten sich die nächsten Gewinne an. Gleichzeitig müssen die Märkte aber auch viele... ► Artikel lesen | |
RHOEN-KLINIKUM | 14,800 | 0,00 % | EQS-HV: RHÖN-KLINIKUM Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 03.06.2025 in Bad Neustadt a. d. Saale mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Bekanntmachung der Einberufung zur Hauptversammlung
RHÖN-KLINIKUM Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung... ► Artikel lesen | |
BICO GROUP | 3,612 | +1,35 % | BICO Group Aktie: Strategische Neuausrichtung | BICO Group verkauft MatTek und Visikol für 80 Millionen US-Dollar an Sartorius und fokussiert sich stärker auf Labortechnik. Zudem stehen Personalwechsel und Quartalszahlen an. Verkauf von Tochtergesellschaften... ► Artikel lesen | |
HIMS & HERS HEALTH | 24,350 | -1,54 % | Comeback-Kandidat im Fokus: Hims & Hers Health mit erster Stabilisierung | Anzeige / WerbungDie Aktie von Hims & Hers Health (ISIN: US4330001060) galt lange als Highflyer unter den wachstumsstarken Digital-Health-Werten - nun kämpft sie um die Trendwende. Nach einem rasanten... ► Artikel lesen | |
M1 KLINIKEN | 16,080 | +2,94 % | M1 Kliniken Aktie: Mitarbeiter begeistert! | HAEMATO AG prüft Verkauf des Pharmageschäfts, um sich auf den Beauty-Sektor zu konzentrieren. Geplante Dividende von 0,50 Euro je Aktie für 2025. Verkauf des Pharmasegments in der EndprüfungAnzeigeSollten... ► Artikel lesen | |
BAXTER | 26,875 | +0,66 % | Seit Mai 2023 kontingentiert: Scopoderm: Baxter will Anfang Mai liefern | ||
LIFEWARD | 1,480 | 0,00 % | Lifeward Ltd.: FDA Issues Clearance for ReWalk 7 Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
JD HEALTH | 4,140 | -0,48 % | JD HEALTH (06618): PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 20, 2025 | ||
COOPER COMPANIES | 73,00 | 0,00 % | CooperCompanies Updates FY25 Outlook | WASHINGTON (dpa-AFX) - While reporting its results for the first quarter on Thursday, medical devices company CooperCompanies (COO), updated its fiscal year 2025 financial guidance. For the... ► Artikel lesen | |
SURGICAL SCIENCE SWEDEN | 12,320 | +1,57 % | Surgical Science Sweden AB: Year-end report 2024: Strong end to the year | FOURTH QUARTER 2024 (OCT - DEC)Net sales amounted to SEK 251.5 (227.3) million, an increase of 11 percent compared with the corresponding period in the preceding year.License revenue amounted to SEK... ► Artikel lesen | |
COMMUNITY HEALTH SYSTEMS | 2,460 | +5,13 % | COMMUNITY HEALTH SYSTEMS INC - 10-Q, Quarterly Report | ||
ONWARD MEDICAL | 4,040 | 0,00 % | ONWARD Medical NV: ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market | Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch
BNY will be ADR depositary bank
Ticker symbol for US investors is ONWRY
EINDHOVEN... ► Artikel lesen | |
SOLENO THERAPEUTICS | 65,50 | +0,46 % | Piper Sandler raises Soleno Therapeutics stock target to $145 | ||
RAMSAY HEALTH CARE | 18,500 | +0,54 % | RAMSAY HEALTH CARE LIMITED: Dividend/Distribution - RHCPA |